Share on StockTwits

Analysts at BMO Capital Markets began coverage on shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) in a research report issued to clients and investors on Monday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating and a $17.00 price target on the stock. BMO Capital Markets’ price target would indicate a potential upside of 78.01% from the stock’s previous close.

Amphastar Pharmaceuticals (NASDAQ:AMPH) traded down 4.08% during mid-day trading on Monday, hitting $9.16. 23,591 shares of the company’s stock traded hands. Amphastar Pharmaceuticals has a 52-week low of $6.67 and a 52-week high of $11.07. The stock’s 50-day moving average is $9.41 and its 200-day moving average is $9.41. The company has a market cap of $397.6 million and a price-to-earnings ratio of 47.04.

Separately, analysts at Jefferies Group initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Monday. They set a “buy” rating and a $14.00 price target on the stock.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.